Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Instituto de Investigación Biomédica de Salamanca · Clinica Universidad de Navarra · +25 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
796
total citations
- FWCI
- 43.48
- Percentile
- 100%
- References
- 33
Citations per year
Authors
25- JFJesús F. San MiguelCorresponding
Instituto de Investigación Biomédica de Salamanca, Clinica Universidad de Navarra, Universidad de Salamanca
- KWKatja Weisel
University Children's Hospital Tübingen
- PMPhilippe Moreau
- MQMartha Q. Lacy
Mayo Clinic, Mayo Clinic in Arizona, Mayo Clinic in Florida
- KSKevin Song
Vancouver General Hospital
Topics & keywords
Topics
Keywords
- Pomalidomide
- Dexamethasone
- Medicine
- Lenalidomide
- Refractory (planetary science)
- Internal medicine
- Multiple myeloma
- Clinical endpoint
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.